PL3171891T3 - Sposób - Google Patents

Sposób

Info

Publication number
PL3171891T3
PL3171891T3 PL15756845.2T PL15756845T PL3171891T3 PL 3171891 T3 PL3171891 T3 PL 3171891T3 PL 15756845 T PL15756845 T PL 15756845T PL 3171891 T3 PL3171891 T3 PL 3171891T3
Authority
PL
Poland
Prior art keywords
way
Prior art date
Application number
PL15756845.2T
Other languages
English (en)
Inventor
Christian Kjellman
Sofia JARNUM
Lena WINSTEDT
Original Assignee
Hansa Biopharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hansa Biopharma AB filed Critical Hansa Biopharma AB
Publication of PL3171891T3 publication Critical patent/PL3171891T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01096—Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase (3.2.1.96)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
PL15756845.2T 2014-07-25 2015-07-10 Sposób PL3171891T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1413240.1A GB201413240D0 (en) 2014-07-25 2014-07-25 Method
PCT/EP2015/065895 WO2016012285A2 (en) 2014-07-25 2015-07-10 Method

Publications (1)

Publication Number Publication Date
PL3171891T3 true PL3171891T3 (pl) 2026-02-23

Family

ID=51587261

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15756845.2T PL3171891T3 (pl) 2014-07-25 2015-07-10 Sposób

Country Status (26)

Country Link
US (3) US10973889B2 (pl)
EP (2) EP3171891B1 (pl)
JP (1) JP6708641B2 (pl)
KR (2) KR20230119267A (pl)
CN (2) CN114949187A (pl)
AU (1) AU2015294125B2 (pl)
BR (1) BR112017001420A2 (pl)
CA (1) CA2955704A1 (pl)
CL (1) CL2017000191A1 (pl)
CO (1) CO2017000571A2 (pl)
DK (1) DK3171891T3 (pl)
EA (1) EA039169B1 (pl)
ES (1) ES3054696T3 (pl)
FI (1) FI3171891T3 (pl)
GB (1) GB201413240D0 (pl)
HR (1) HRP20251560T1 (pl)
IL (1) IL249981B (pl)
LT (1) LT3171891T (pl)
MX (1) MX2017001138A (pl)
MY (1) MY196858A (pl)
PL (1) PL3171891T3 (pl)
PT (1) PT3171891T (pl)
RS (1) RS67520B1 (pl)
SG (1) SG11201700172WA (pl)
SI (1) SI3171891T1 (pl)
WO (1) WO2016012285A2 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201413240D0 (en) * 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
WO2017210360A1 (en) 2016-05-31 2017-12-07 Cardiovax, Llc Methods for diagnosing and treating systemic lupus erythematosus
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
UA130214C2 (uk) 2018-07-20 2025-12-24 Момента Фармасьютикалз, Інк. Фармацевтична композиція антитіл проти fcrn
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
CA3149395A1 (en) * 2019-08-01 2021-02-04 Memorial Sloan-Kettering Cancer Center Cells for improved immunotherapy and uses thereof
CN114630678A (zh) * 2019-08-01 2022-06-14 詹森生物科技公司 FcRn抗体及其使用方法
JP2023512014A (ja) 2020-01-28 2023-03-23 フリーライン セラピューティクス リミテッド ウイルスベクターに対する中和抗体力価を決定するための改善されたアッセイ
GB202002072D0 (en) * 2020-02-14 2020-04-01 Hansa Biopharma AB immunoglobulin detection and associated therapies
GB202003129D0 (en) * 2020-03-04 2020-04-15 Hansa Biopharma AB Conditioning regimen for transplant of stem cells
GB202007431D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Cysteine protease
GB202007434D0 (en) 2020-05-19 2020-07-01 Hansa Biopharma AB Methods
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
EP4215208A4 (en) * 2020-09-21 2024-11-20 Shanghai Bao Pharmaceuticals Co., Ltd. PHARMACEUTICAL COMBINATION AND USE THEREOF
WO2022076556A2 (en) 2020-10-07 2022-04-14 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy disorders including limb girdle 2i (lgmd2i)
CA3216491A1 (en) 2021-04-16 2022-10-20 Asklepios Biopharmaceutical, Inc. Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response
EP4079848A1 (en) 2021-04-22 2022-10-26 Genovis Ab Immunoglobulin cleaving enzyme
WO2022251253A1 (en) 2021-05-24 2022-12-01 Provention Bio, Inc. Methods for treating type 1 diabetes
WO2023084095A2 (en) 2021-11-15 2023-05-19 Hansa Biopharma AB Methods for enhancing adoptive cell transfer immunotherapies
IL315305A (en) 2022-03-17 2024-10-01 Astrazeneca Ireland Ltd Improved IgG-degrading enzymes and methods of using them
WO2024108137A2 (en) 2022-11-18 2024-05-23 Seismic Therapeutic, Inc. Fc fusion molecules and uses thereof
CN116087528A (zh) * 2022-12-27 2023-05-09 华中科技大学同济医学院附属同济医院 一种sqtsm1蛋白在卵巢早衰的应用
JP2026501731A (ja) 2023-01-06 2026-01-16 サイズミック セラピューティク インコーポレイテッド プロテアーゼ変異体及びその使用
WO2025248469A1 (en) * 2024-05-28 2025-12-04 Biohaven Therapeutics Ltd. TREATMENT OF IgG-RELATED DISEASES
WO2025256978A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Variants of igm and igg cleaving enzymes
WO2025256977A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Novel igm and igg cleaving enzymes
GB202413764D0 (en) 2024-09-18 2024-10-30 Genovis Ab Immunoglobulin proteases and their uses

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
JPH0612624B2 (ja) * 1984-06-20 1994-02-16 株式会社日立製作所 半導体集積回路装置
DE69723888T2 (de) * 1996-05-09 2004-05-27 The General Hospital Corp., Boston Gemischter Chimerismus und Toleranz
WO2006131347A2 (en) * 2005-06-09 2006-12-14 Hansa Medical Ab Use of the ides proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection
GB0511769D0 (en) * 2005-06-09 2005-07-20 Hansa Medical Ab Treatment
GB2427360A (en) * 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
GB0624874D0 (en) * 2006-12-13 2007-01-24 Hansa Medical Ab Treatment
JP5722627B2 (ja) * 2007-09-14 2015-05-27 ジェノビス エービー ＦＣガンマ受容体−ＩｇＧ複合体の解離、ならびにＩｇＧの精製および検出のための方法およびキット
GB201115841D0 (en) 2011-09-13 2011-10-26 Genovis Ab Protein and method
GB201201314D0 (en) * 2012-01-26 2012-03-07 Isis Innovation Composition
TWI626491B (zh) 2012-12-10 2018-06-11 布萊恩荷登視覺協會 用於視力校正之具有一或多個多正焦區域之眼用光學透鏡
GB201413240D0 (en) * 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502305D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502306D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB202007434D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Methods

Also Published As

Publication number Publication date
US20210260173A1 (en) 2021-08-26
PT3171891T (pt) 2025-11-25
KR20230119267A (ko) 2023-08-16
SG11201700172WA (en) 2017-02-27
NZ728265A (en) 2024-03-22
BR112017001420A2 (pt) 2017-11-28
WO2016012285A2 (en) 2016-01-28
EP3171891B1 (en) 2025-09-10
GB201413240D0 (en) 2014-09-10
CN114949187A (zh) 2022-08-30
US20170209550A1 (en) 2017-07-27
EP4663755A2 (en) 2025-12-17
RS67520B1 (sr) 2025-12-31
HRP20251560T1 (hr) 2026-01-16
IL249981A0 (en) 2017-03-30
CN106714834A (zh) 2017-05-24
AU2015294125B2 (en) 2020-10-15
EP4663755A3 (en) 2026-04-15
IL249981B (en) 2022-08-01
US20260000739A1 (en) 2026-01-01
DK3171891T3 (da) 2025-12-15
HK1232122A1 (en) 2018-01-05
CO2017000571A2 (es) 2017-06-20
SI3171891T1 (sl) 2026-01-30
CL2017000191A1 (es) 2017-08-25
US10973889B2 (en) 2021-04-13
KR102565244B1 (ko) 2023-08-10
KR20170039243A (ko) 2017-04-10
MY196858A (en) 2023-05-05
US12397044B2 (en) 2025-08-26
MX2017001138A (es) 2017-06-07
EA039169B1 (ru) 2021-12-13
JP2017522384A (ja) 2017-08-10
EP3171891A2 (en) 2017-05-31
AU2015294125A1 (en) 2017-02-02
CA2955704A1 (en) 2016-01-28
EA201790192A1 (ru) 2017-09-29
ES3054696T3 (en) 2026-02-05
LT3171891T (lt) 2025-12-29
FI3171891T3 (fi) 2025-12-08
JP6708641B2 (ja) 2020-06-10
WO2016012285A3 (en) 2016-04-14

Similar Documents

Publication Publication Date Title
FIC20250036I1 (fi) Epkoritamabi
FIC20240044I1 (fi) Odronekstamabi
FIC20230037I1 (fi) Glofitamabi
FIC20240015I1 (fi) Zilbrysq - tsilukoplaani
FIC20220017I1 (fi) Lonapegsomatropiini
DK3183051T3 (da) Væske-til-luftmembranenergivekslere
DK3134402T3 (da) 4-amino-imidazoquinolinforbindelser
DK3211743T3 (da) Ø-til-netværk-omskiftningsfremgangsmåde
FIC20265009I1 (fi) Brensocatib
DK3006072T3 (da) Karadgang
DK3222714T3 (da) Phytasemutanter
FIC20230016I1 (fi) Nirsevimabi
FIC20240047I1 (fi) Frukintinibi
EP4011484C0 (en) CARBONIC ANHYDRASE OF THERMOVIBRIO AMMONIFICANS
DK4242916T3 (da) Forstøver
DK3183340T3 (da) Termolabile exonukleaser
DE112015001664A5 (de) Betätigungsaktuator
DK3154703T3 (da) Fuldkappe-snekkecentrifuge
DE112015005041A5 (de) Gargerätevorrichtung
DK3110439T3 (da) Pcsk9-vacciner
DE102014000623A8 (de) Halbhohlnietelement
DK3009858T3 (da) Skyradar
FI20145913A (fi) Staattorimekanismi
DE112015001633A5 (de) Betätigungsaktuator
DK3447493T3 (da) Proteinrettede ortologer